scholarly article | Q13442814 |
P356 | DOI | 10.1002/IJC.30500 |
P698 | PubMed publication ID | 27813061 |
P50 | author | Rakhee Vatsa | Q57081396 |
P2093 | author name string | Amanjit Bal | |
Gurpreet Singh | |||
Bhagwant R Mittal | |||
Jaya Shukla | |||
Madan Parmar | |||
Devinder K Dhawan | |||
Priya Bhusari | |||
P2860 | cites work | Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 | Q25938983 |
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy | Q33212260 | ||
Quantification of bifunctional diethylenetriaminepentaacetic acid derivative conjugation to monoclonal antibodies by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry | Q33291285 | ||
Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma | Q33372470 | ||
Evaluating the potential of 188Re-SOCTA-trastuzumab as a new radioimmunoagent for breast cancer treatment | Q33404229 | ||
Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma | Q33767100 | ||
In Vitro and In Vivo Pre-Clinical Analysis of a F(ab')(2) Fragment of Panitumumab for Molecular Imaging and Therapy of HER1 Positive Cancers | Q35162293 | ||
(64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients | Q35266784 | ||
Labeling and Biological Evaluation of (99m)Tc-HYNIC-Trastuzumab as a Potential Radiopharmaceutical for In Vivo Evaluation of HER2 Expression in Breast Cancer. | Q37100372 | ||
Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. | Q37123529 | ||
Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer | Q37626334 | ||
Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using (111)In-trastuzumab (Herceptin) Fab fragments. | Q40462071 | ||
Quality control of positron emission tomography radiopharmaceuticals: An institutional experience | Q42252521 | ||
An improved method for conjugating monoclonal antibodies with N-hydroxysulfosuccinimidyl DOTA. | Q43582043 | ||
64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer | Q44650607 | ||
Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging | Q44944204 | ||
Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer | Q48252174 | ||
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update | Q57130157 | ||
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | breast cancer | Q128581 |
P304 | page(s) | 938-947 | |
P577 | publication date | 2016-11-18 | |
P1433 | published in | International Journal of Cancer | Q332492 |
P1476 | title | Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients | |
P478 | volume | 140 |
Q57110662 | Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast Cancer |
Q55438401 | Drug conjugates—an emerging approach to treat breast cancer. |
Q89622510 | Ovarian Cancer Targeted Theranostics |
Q38691472 | Radioimmunoconjugates for treating cancer: recent advances and current opportunities |
Q49700421 | Targeting HER2 in Nuclear Medicine for Imaging and Therapy |
Q93103176 | Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC) |
Search more.